UKRI announces six research initiatives into COVID-19 and ethnicity
The UKRI and NIHR will fund projects worth £4.3 million to investigate the disproportionate death rate from COVID-19 among people from BAME backgrounds.
List view / Grid view
The UKRI and NIHR will fund projects worth £4.3 million to investigate the disproportionate death rate from COVID-19 among people from BAME backgrounds.
Sandoz plans to invest €150 million and the Austrian government €50 million into integrated antibiotic manufacturing operations at Kundl.
The UK government has committed £100 million to establish a centre to scale up COVID-19 vaccine and gene therapy manufacturing.
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
Marie Manley and co-authors from Sidley Austin explain the updates to regulations in the EU and UK in light of the COVID-19 coronavirus pandemic.
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
A private-public consortium to develop pre-filled syringe packaging has been backed by Jefferies, including a seed capital commitment of at least $10 million.
Due to the COVID-19 outbreak, India has decided to invest $1.3 billion into its internal drug manufacturing capabilities, says a new report.
The UK government has pledged funding of £22 billion per year into R&D by 2025 in its Budget, just days after a further £46 million was invested into coronavirus research.
Researchers have found that oncology therapies had the most investment in non-industry sponsored clinical trials last year.
Researchers have revealed the countries which spend the most on R&D as compared to revenue, as well as the companies in the UK investing in research.
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
Researchers have found that the development and evaluation of new treatments received the most funding in the UK over the past 14 years.
Research has revealed that the biotechnology industry was worth £1.3 billion in 2019, marking its third-highest year for investment.